Metformin and Flutamide Combination Therapy's Efficacy and Safety in Prostate Cancer Cell Lines
Abstract
Background: Considering the hepatotoxicity and other side effects associated with flutamide as a first-line treatment for prostate cancer (PCa), this study aimed to evaluate metformin as a potential anticancer agent to reduce the required dose of flutamide and thereby minimize its adverse effects.
Method: We assessed the influence of metformin, flutamide, and metformin-flutamide combination therapy on LNCaP, DU145, and PC3 cell lines, which represent human PCa. The tests include wound-healing assay, colony formation assay (CFA), analysis of apoptosis (programmed cell death) and cell cycle by flow cytometry, gene expression at the mRNA level by real-time PCR (BAX/BCL2, E-cadherin, Snail, HIF1α, VEGFC, and KLK3 genes), and assessment of the treatments' hepatotoxicity potential via measuring AST and ALT values.
Result: To determine the IC50 (half-maximal inhibitory concentration) values, cell lines were treated with different concentrations of the drugs. The IC50 values for metformin (800 μM) in the three cell lines and for flutamide (12 μM for PC3 and 10 μM for LNCaP/DU145), as determined by MTT assay, were confirmed by flow cytometry, indicating significant cell cycle arrest at the G0/G1 phase. The combination of metformin and flutamide significantly increased the BAX/BCL2 mRNA ratio in all three cell lines (p KLK3 (p HIF1α (p VEGFC (p EMT pathway genes in PC3 and LNCaP (p < 0.01). Liver injury assessment reported a reduction in flutamide's hepatotoxicity in combination with…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.